HK5796A - Polymer, production and use thereof - Google Patents

Polymer, production and use thereof Download PDF

Info

Publication number
HK5796A
HK5796A HK5796A HK5796A HK5796A HK 5796 A HK5796 A HK 5796A HK 5796 A HK5796 A HK 5796A HK 5796 A HK5796 A HK 5796A HK 5796 A HK5796 A HK 5796A
Authority
HK
Hong Kong
Prior art keywords
water
polymer
lactic acid
high molecular
acid
Prior art date
Application number
HK5796A
Other languages
English (en)
French (fr)
Inventor
Yamamoto Masaki
Okada Hiroaki
Ogawa Yasuaki
Miyagawa Tsutomu
Original Assignee
Takeda Pharmaceutical Company Limited
Wako Pure Chemical Industries, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=14197161&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK5796(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical Company Limited, Wako Pure Chemical Industries, Ltd. filed Critical Takeda Pharmaceutical Company Limited
Publication of HK5796A publication Critical patent/HK5796A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/02—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds
    • C08G63/06—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds derived from hydroxycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/02—Making microcapsules or microballoons
    • B01J13/06—Making microcapsules or microballoons by phase separation
    • B01J13/12—Making microcapsules or microballoons by phase separation removing solvent from the wall-forming material solution
    • B01J13/125—Making microcapsules or microballoons by phase separation removing solvent from the wall-forming material solution by evaporation of the solvent

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Polymers & Plastics (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Separation, Recovery Or Treatment Of Waste Materials Containing Plastics (AREA)
  • Processing Of Solid Wastes (AREA)

Claims (8)

  1. Verfahren zur Herstellung eines biologisch abbaubaren hochmolekularen Polymers mit einem Gewichtsmittel des Molekulargewichts von 5 000 bis 35 000 und mit 50 bis 100 Mol-% Milchsäure-Resten und 50 bis 0 Mol-% Glycolsäure-Resten, bestehend aus dem Herstellen des Polymers aus Milchsäure oder Milchsäure und Glycolsäure unter wäßrigen Reaktionsbedingungen und danach dem Reduzieren des Gehalts der Milchsäure oder der Milchsäure und Glycolsäure in dem Polymer auf einen Wert von weniger als 0,01 mol auf 100 g des Polymers durch Extraktion mit Wasser oder einem Gemisch aus Wasser und einem wasserlöslichen organischen Lösungsmittel, dadurch gekennzeichnet, daß dieser Schritt der Extraktion das Auflösen des nicht weniger als 0,01 Mol-% Milchsäure oder Milchsäure und Glycolsäure enthaltenden Polymers in der 3-bis 20-fachen Menge (Gew./Vol.) eines organischen Lösungsmittels und das Eingießen der resultierenden Lösung in Wasser unter Rühren bei einer Temperatur von 20 °C bis 70 °C umfaßt.
  2. Verfahren nach Anspruch 1, worin der Gehalt der Milchsäure oder der Milchsäure und Glycolsäure auf einen Wert von 0,0055 mol oder weniger auf 100 g des Polymers reduziert wird.
  3. Verfahren nach Anspruch 1 oder Anspruch 2, worin das wasserlösliche organische Lösungsmittel Ethanol ist.
  4. Verfahren zur Herstellung einer Mikrokapsel zur verlängerten Abgabe eines injizierbaren Stoffes, enthaltend eine wirksame Menge eines aktiven Inhaltsstoffs und als Exzipienten ein biologisch abbaubares hochmolekulares Polymer, wie es in Anspruch 1 definiert ist, mit einem Gehalt an Milchsäure oder an Milchsäure und Glycolsäure von weniger als 0,01 mol auf 100 g des Polymers oder, wie es in Anspruch 2 definiert ist, mit einem Gehalt an Milchsäure oder an Milchsäure und Glycolsäure von weniger als 0,0055 mol auf 100 g des Polymers, umfassend das Herstellen einer Wasser/Öl(W/O)-Emulsion mit einer den aktiven Inhaltsstoff enthaltenden wäßrigen Lösung, die als innere Wasser-Phase dient, und einer das biologisch abbaubare Polymer enthaltenden Lösung, die als Öl-Phase dient, das Dispergieren der Emulsion in einer Wasser(W)-Phase zur Bildung einer (W/O)/W-Emulsion und das In-Berührung-Bringen der resultierenden Emulsion mit einer dritten wäßrigen Phase zur Bildung einer (W/O)/W-Ternär-Phasen-Emulsion, wobei das Lösungsmittel in der Öl-Phase desorbiert wird.
  5. Verfahren nach Anspruch 4, worin der aktive Inhaltsstoff ein wasserlösliches Peptid ist.
  6. Verwendung eines biologisch abbaubaren hochmolekularen Polymers als Matrix in einer Mikrokapsel für die verlängerte Abgabe eines aktiven Inhaltsstoffs aus dieser Mikrokapsel, wobei das Polymer eines ist, wie es in Anspruch 1 definiert ist.
HK5796A 1985-05-07 1996-01-11 Polymer, production and use thereof HK5796A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP9761785 1985-05-07

Publications (1)

Publication Number Publication Date
HK5796A true HK5796A (en) 1996-01-19

Family

ID=14197161

Family Applications (1)

Application Number Title Priority Date Filing Date
HK5796A HK5796A (en) 1985-05-07 1996-01-11 Polymer, production and use thereof

Country Status (8)

Country Link
US (2) US4728721A (de)
EP (1) EP0202065B1 (de)
JP (2) JP2551756B2 (de)
AT (1) ATE87946T1 (de)
CA (1) CA1262005A (de)
DE (1) DE3688213T2 (de)
HK (1) HK5796A (de)
HU (1) HU196703B (de)

Families Citing this family (177)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60100516A (ja) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
DE3641692A1 (de) * 1986-12-06 1988-06-09 Boehringer Ingelheim Kg Katalysatorfreie resorbierbare homopolymere und copolymere
US4897268A (en) * 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
JP2670680B2 (ja) * 1988-02-24 1997-10-29 株式会社ビーエムジー 生理活性物質含有ポリ乳酸系微小球およびその製造法
US6323307B1 (en) 1988-08-08 2001-11-27 Cargill Dow Polymers, Llc Degradation control of environmentally degradable disposable materials
US5424346A (en) * 1988-08-08 1995-06-13 Ecopol, Llc Biodegradable replacement of crystal polystyrene
WO1990001521A1 (en) * 1988-08-08 1990-02-22 Battelle Memorial Institute Degradable thermoplastic from lactides
AU634723B2 (en) * 1988-08-08 1993-03-04 Biopak Technology, Ltd. Degradable thermoplastic from lactides
US5180765A (en) * 1988-08-08 1993-01-19 Biopak Technology, Ltd. Biodegradable packaging thermoplastics from lactides
JP2714454B2 (ja) * 1988-11-07 1998-02-16 三井東圧化学株式会社 生体吸収性ポリエステルの製造方法
DE3936191C2 (de) * 1989-10-31 1996-10-17 Boehringer Ingelheim Kg Neue Copolymere aus Milchsäure und Weinsäure, ihre Herstellung sowie ihre Verwendung
JP2653255B2 (ja) * 1990-02-13 1997-09-17 武田薬品工業株式会社 長期徐放型マイクロカプセル
MY107937A (en) * 1990-02-13 1996-06-29 Takeda Chemical Industries Ltd Prolonged release microcapsules.
US5075115A (en) * 1990-04-02 1991-12-24 Fmc Corporation Process for polymerizing poly(lactic acid)
EP0452111B1 (de) * 1990-04-13 1998-07-15 Takeda Chemical Industries, Ltd. Biologisch abbaubare hochmolekulare Polymere, ihre Herstellung und ihre Verwendung
MY108621A (en) * 1990-08-01 1996-10-31 Novartis Ag Polylactide preparation and purification
BR9106821A (pt) * 1990-09-06 1993-07-13 Battelle Memorial Institute Termoplasticos para embalagem provenientes de acido latico
PH31064A (en) * 1990-09-07 1998-02-05 Nycomed As Of Nycoveten Polymers containing diester units.
ZA918168B (en) 1990-10-16 1993-04-14 Takeda Chemical Industries Ltd Prolonged release preparation and polymers thereof.
IT1249045B (it) * 1991-02-21 1995-02-11 Himont Inc Processo per la sintesi allo stato solido di polimeri dell'acido lattico e prodotti cosi ottenuti
CH683149A5 (fr) * 1991-07-22 1994-01-31 Debio Rech Pharma Sa Procédé pour la préparation de microsphères en matériau polymère biodégradable.
US5258488A (en) * 1992-01-24 1993-11-02 Cargill, Incorporated Continuous process for manufacture of lactide polymers with controlled optical purity
US5247058A (en) * 1992-01-24 1993-09-21 Cargill, Incorporated Continuous process for manufacture of lactide polymers with controlled optical purity
US5247059A (en) * 1992-01-24 1993-09-21 Cargill, Incorporated Continuous process for the manufacture of a purified lactide from esters of lactic acid
US5142023A (en) * 1992-01-24 1992-08-25 Cargill, Incorporated Continuous process for manufacture of lactide polymers with controlled optical purity
US6005067A (en) * 1992-01-24 1999-12-21 Cargill Incorporated Continuous process for manufacture of lactide polymers with controlled optical purity
US6326458B1 (en) 1992-01-24 2001-12-04 Cargill, Inc. Continuous process for the manufacture of lactide and lactide polymers
FR2692147B1 (fr) * 1992-06-15 1995-02-24 Centre Nat Rech Scient Microsphères en polymère biorésorbable exemptes de tensioactif, leur préparation et leur application comme médicament.
EP0615555B1 (de) * 1992-10-02 2001-03-21 Cargill, Incorporated Schmelzstabiles lactidpolymergewebe und verfahren zu seiner herstellung
US6005068A (en) 1992-10-02 1999-12-21 Cargill Incorporated Melt-stable amorphous lactide polymer film and process for manufacture thereof
WO1994008090A1 (en) * 1992-10-02 1994-04-14 Cargill, Incorporated Paper having a melt-stable lactide polymer coating and process for manufacture thereof
US5338822A (en) * 1992-10-02 1994-08-16 Cargill, Incorporated Melt-stable lactide polymer composition and process for manufacture thereof
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US6090925A (en) 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US5643605A (en) * 1993-10-25 1997-07-01 Genentech, Inc. Methods and compositions for microencapsulation of adjuvants
US6913767B1 (en) 1993-10-25 2005-07-05 Genentech, Inc. Compositions for microencapsulation of antigens for use as vaccines
US6080429A (en) * 1993-10-25 2000-06-27 Genentech, Inc. Method for drying microspheres
US5626862A (en) 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
TW448055B (en) * 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
US5942253A (en) * 1995-10-12 1999-08-24 Immunex Corporation Prolonged release of GM-CSF
SE505146C2 (sv) * 1995-10-19 1997-06-30 Biogram Ab Partiklar för fördröjd frisättning
DE19545257A1 (de) 1995-11-24 1997-06-19 Schering Ag Verfahren zur Herstellung von morphologisch einheitlichen Mikrokapseln sowie nach diesem Verfahren hergestellte Mikrokapseln
US6303134B1 (en) 1996-08-29 2001-10-16 Advanced Research And Technology Institute, Inc. Pharmacotherapeutic process and composition for central nervous system disorders
US20070185032A1 (en) * 1996-12-11 2007-08-09 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
US5968895A (en) 1996-12-11 1999-10-19 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
US6126919A (en) * 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
US5989463A (en) * 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6217844B1 (en) * 1998-04-27 2001-04-17 Praecis Pharmaceuticals, Inc. Methods for detecting lesions in dense breast tissue using LHRH antagonists
US6565874B1 (en) * 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
US6458387B1 (en) * 1999-10-18 2002-10-01 Epic Therapeutics, Inc. Sustained release microspheres
ES2169980B1 (es) 1999-12-17 2003-11-01 Lipotec Sa Microcapsulas para la liberacion prolongada de farmacos.
TW200800298A (en) 2000-01-27 2008-01-01 Zentaris Ag Compressed microparticles for dry injection
CA2406846C (en) * 2000-04-21 2008-11-18 Advanced Research And Technology Institute, Inc. Pharmacotherapeutic process and composition for central nervous system disorders
US7019106B2 (en) † 2000-08-07 2006-03-28 Wako Pure Chemical Industries, Ltd. Lactic acid polymer and process for producing the same
US6362308B1 (en) 2000-08-10 2002-03-26 Alkermes Controlled Therapeutics Inc. Ii Acid end group poly(d,l-lactide-co-glycolide) copolymers high glycolide content
WO2002043580A2 (en) 2000-10-27 2002-06-06 Epic Therapeutics, Inc. Production of microspheres
US8470359B2 (en) 2000-11-13 2013-06-25 Qlt Usa, Inc. Sustained release polymer
US7252842B2 (en) 2000-12-21 2007-08-07 Alrise Biosystems Gmbh Induced phase transition method for the production of microparticles containing hydrophilic active agents
CA2451187C (en) 2001-06-22 2012-08-14 Southern Biosystems, Inc. Zero-order prolonged release coaxial implants
TWI332407B (en) 2001-06-29 2010-11-01 Takeda Chemical Industries Ltd Controlled release composition and method of producting the same
TWI225416B (en) 2001-06-29 2004-12-21 Takeda Chemical Industries Ltd Sustained-release composition and process for producing the same
JP4612239B2 (ja) * 2001-07-18 2011-01-12 三井化学株式会社 生体吸収性ポリヒドロキシカルボン酸の製造方法
US20080026068A1 (en) * 2001-08-16 2008-01-31 Baxter Healthcare S.A. Pulmonary delivery of spherical insulin microparticles
EP1418890B1 (de) * 2001-08-16 2008-05-14 Baxter International Inc. Darreichungsformen welche mikropartikel und treibgas enthalten
JP2003192773A (ja) * 2001-12-26 2003-07-09 Mitsui Chemicals Inc 生体吸収性ポリヒドロキシカルボン酸及びその製造法
US6849600B2 (en) * 2002-03-25 2005-02-01 The Regents Of The University Of California, Berkeley Corticotropin-releasing hormone analogs
US20060193825A1 (en) * 2003-04-29 2006-08-31 Praecis Phamaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
US20050112087A1 (en) * 2003-04-29 2005-05-26 Musso Gary F. Pharmaceutical formulations for sustained drug delivery
WO2005035088A2 (en) * 2003-07-18 2005-04-21 Baxter International, Inc. Method for preparing small spherical by controlled phase separation
US20070092452A1 (en) * 2003-07-18 2007-04-26 Julia Rashba-Step Methods for fabrication, uses, compositions of inhalable spherical particles
US20050142205A1 (en) * 2003-07-18 2005-06-30 Julia Rashba-Step Methods for encapsulating small spherical particles prepared by controlled phase separation
JP2007508240A (ja) * 2003-07-22 2007-04-05 バクスター・インターナショナル・インコーポレイテッド 低分子量有機分子の小球状粒子ならびにその調製方法および使用方法
US20080318837A1 (en) * 2003-12-26 2008-12-25 Nastech Pharmaceutical Company Inc. Pharmaceutical Formation For Increased Epithelial Permeability of Glucose-Regulating Peptide
US20060210614A1 (en) * 2003-12-26 2006-09-21 Nastech Pharmaceutical Company Inc. Method of treatment of a metabolic disease using intranasal administration of exendin peptide
US20050143303A1 (en) * 2003-12-26 2005-06-30 Nastech Pharmaceutical Company Inc. Intranasal administration of glucose-regulating peptides
US20060074025A1 (en) * 2003-12-26 2006-04-06 Nastech Pharmaceutical Company Inc. Therapeutic formulations for transmucosal administration that increase glucagon-like peptide-1 bioavailability
TW200529890A (en) * 2004-02-10 2005-09-16 Takeda Pharmaceutical Sustained-release preparations
JP4403846B2 (ja) * 2004-03-22 2010-01-27 東レ株式会社 ポリ乳酸のラクチド除去法
JP4403845B2 (ja) * 2004-03-22 2010-01-27 東レ株式会社 ラクチド含有量が少ないポリ乳酸の製造方法
EP1753404A1 (de) * 2004-05-12 2007-02-21 Baxter International Inc. Mikrokügelchen mit protein; die bei hohen konzentrationen des mittels injizierbar sind
CA2566079A1 (en) * 2004-05-12 2005-12-01 Terrence L. Scott Nucleic acid microspheres, production and delivery thereof
WO2005114322A2 (en) * 2004-05-12 2005-12-01 Massachusetts Institute Of Technology Manufacturing process, such as three-dimensional printing, including solvent vapor filming and the like
US8728525B2 (en) * 2004-05-12 2014-05-20 Baxter International Inc. Protein microspheres retaining pharmacokinetic and pharmacodynamic properties
WO2005112885A2 (en) * 2004-05-12 2005-12-01 Baxter International Inc. Oligonucleotide-containing microspheres, their use for the manufacture of a medicament for treating diabetes type 1
TW200613012A (en) * 2004-07-02 2006-05-01 Takeda Pharmaceuticals Co Sustained-release composition, process for producing the same and use of the same
ATE424848T1 (de) 2004-08-12 2009-03-15 Quest Pharmaceutical Services Pharmazeutische zusammensetzungen für die kontrollierte freigabe von biologischen wirkstoffen
US20070254314A1 (en) * 2004-09-16 2007-11-01 Geier Mark R Methods of treating autism and autism spectrum disorders
US8541413B2 (en) * 2004-10-01 2013-09-24 Ramscor, Inc. Sustained release eye drop formulations
US9993558B2 (en) 2004-10-01 2018-06-12 Ramscor, Inc. Sustained release eye drop formulations
EP3173072A1 (de) * 2004-10-01 2017-05-31 Ramscor, Inc. Einfach implantierbare wirkstoffzusammensetzungen mit verzögerter freisetzung
US20080038316A1 (en) * 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
US8394410B2 (en) * 2005-01-20 2013-03-12 Massachusetts Institute Of Technology Soft polylactides
MX2007013356A (es) * 2005-04-27 2008-03-26 Baxter Int Microparticulas modificadas en la superficie y metodos de formacion y uso de las mismas.
ATE382337T1 (de) * 2005-04-28 2008-01-15 Nipro Corp Bioabsorbierbare pharmazeutische zusammensetzung enthaltend einen plga-copolymer
US8840876B2 (en) * 2005-05-19 2014-09-23 Ethicon, Inc. Antimicrobial polymer compositions and the use thereof
US20070106271A1 (en) * 2005-11-09 2007-05-10 Searete Llc, A Limited Liability Corporation Remote control of substance delivery system
WO2007067964A2 (en) * 2005-12-08 2007-06-14 Nastech Pharmaceutical Company Inc. Mucosal delivery of stabilized formulations of exendin
US20070154546A1 (en) * 2005-12-30 2007-07-05 Zhang Jack Y Sustained release pharmaceutical compositions
AU2007207618B2 (en) 2006-01-18 2011-03-24 Foresee Pharmaceuticals Co., Ltd. Pharmaceutical compositions with enhanced stability
US20070179276A1 (en) * 2006-01-31 2007-08-02 Purac Biochem Bv Method for the purification of resorbable polymers from residual monomers
JP2009525372A (ja) * 2006-01-31 2009-07-09 ピュラック バイオケム ビー．ブイ． 残留モノマーから吸収性ポリマーを精製する方法
US20070281031A1 (en) * 2006-06-01 2007-12-06 Guohan Yang Microparticles and methods for production thereof
RU2456018C2 (ru) 2006-07-11 2012-07-20 КьюПиЭс, ЭлЭлСи Фармацевтические композиции для доставки пептидов с замедленным высвобождением
EP2647712A3 (de) * 2006-08-04 2013-11-20 Baxter International Inc Zusammensetzung auf Mikrokügelchenbasis zur Vorbeugung und/oder Umkehrung einer Neuerkrankung an autoimmun bedingter Diabetes
WO2008060786A2 (en) * 2006-10-06 2008-05-22 Baxter International Inc. Microencapsules containing surface-modified microparticles and methods of forming and using the same
US8076448B2 (en) 2006-10-11 2011-12-13 Tolmar Therapeutics, Inc. Preparation of biodegradable polyesters with low-burst properties by supercritical fluid extraction
US7695929B2 (en) 2006-11-01 2010-04-13 Ventana Medical Systems, Inc. Haptens, hapten conjugates, compositions thereof and method for their preparation and use
JP4564098B2 (ja) 2006-12-18 2010-10-20 武田薬品工業株式会社 徐放性組成物およびその製造法
DK3660073T3 (da) 2007-02-15 2023-09-18 Tolmar International Ltd Poly(lactid-co-glycolid) med lav sprængning
US8323685B2 (en) * 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing compositions containing microparticles
US8367427B2 (en) * 2008-08-20 2013-02-05 Baxter International Inc. Methods of processing compositions containing microparticles
US8323615B2 (en) * 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing multi-phasic dispersions
US20100047292A1 (en) * 2008-08-20 2010-02-25 Baxter International Inc. Methods of processing microparticles and compositions produced thereby
US8741259B2 (en) 2008-10-20 2014-06-03 Marvin C. Gershengorn Low molecular weight thyroid stimulating hormone receptor (TSHR) agonists
US8653086B2 (en) 2008-10-21 2014-02-18 Oregon Health & Science University Naphthamides as anticancer agents
WO2010111238A2 (en) * 2009-03-23 2010-09-30 Micell Technologies, Inc. Improved biodegradable polymers
EP2246063A1 (de) 2009-04-29 2010-11-03 Ipsen Pharma S.A.S. GnRH Analoge enthaltende Retardformulierungen
WO2011005939A2 (en) 2009-07-09 2011-01-13 Mayo Foundation For Medical Education And Research Long acting atrial natriuretic peptide (la-anp) and methods for use thereof
US9365612B2 (en) 2010-01-29 2016-06-14 United States Of America As Represented By The Secretary, Department Of Health And Human Services Caspase inhibitors
EP2563777A4 (de) 2010-04-08 2013-09-04 Us Health Inverse agonisten und neutrale agonisten für den tsh-rezeptor
WO2012125486A1 (en) 2011-03-11 2012-09-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Combination chemotherapy for treating cancer
EP2685985B1 (de) 2011-03-17 2016-08-31 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Verfahren zur behandlung von leukämie und erkrankungen durch cbf- und runx1-proteine
CN107090028A (zh) 2011-08-30 2017-08-25 梅约医学教育与研究基金会 利钠多肽
WO2013039792A1 (en) 2011-09-12 2013-03-21 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Immunogens based on an hiv-1 gp120 v1v2 epitope
US20140234360A1 (en) 2011-09-30 2014-08-21 The United States of America, as represented by the Secretary, Dept.of Health and Human Services Influenza vaccine
WO2013103896A1 (en) 2012-01-06 2013-07-11 Mayo Foundation For Medical Education And Research Treating cardiovascular or renal diseases
US9249103B2 (en) 2012-01-13 2016-02-02 Oregon Health & Science University Compounds, compositions and associated methods comprising 3-aryl quinolines
WO2013184202A1 (en) 2012-06-08 2013-12-12 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Fbxo3 inhibitors
CA2889697C (en) 2012-11-13 2023-03-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cannabinoid receptor mediating compounds
US9775895B2 (en) 2012-12-12 2017-10-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services HIV therapeutics and methods of making and using same
PT2970398T (pt) 2013-03-13 2024-06-07 The Us Secretary Department Ofhealth And Human Servic Proteínas f de pré-fusão do vsr e sua utilização
BR112015028760A2 (pt) 2013-05-16 2017-07-25 Us Health compostos para inibição de cepas de integrase do hiv-1 resistentes a drogas
CN103300120B (zh) * 2013-06-25 2015-04-22 南京工业大学 一种绿色家禽家畜脱毛剂及其制备方法
EP3046561B1 (de) 2013-09-20 2023-02-22 University of Pittsburgh - Of the Commonwealth System of Higher Education Verbindungen zur behandlung von prostatakrebs
US10398772B2 (en) 2014-01-08 2019-09-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Ras pathways as markers of protection against HIV and methods to improve vaccine efficacy
CN106660968B (zh) 2014-05-09 2020-02-07 美国政府(由卫生和人类服务部的部长所代表) 吡唑衍生物及其作为大麻素受体介体的用途
ES2914099T3 (es) 2014-08-25 2022-06-07 Salk Inst For Biological Studi Inhibidores novedosos de ULK1 y métodos de uso de los mismos
WO2016037154A1 (en) 2014-09-04 2016-03-10 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Recombinant hiv-1 envelope proteins and their use
WO2016064716A1 (en) 2014-10-20 2016-04-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Combination therapy of tshr antagonist and igfr inhibitor
US10420834B2 (en) 2014-12-24 2019-09-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant metapneumovirus F proteins and their use
WO2016112036A1 (en) 2015-01-05 2016-07-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Myc g-quadruplex stabilizing small molecules and their use
JP2018510849A (ja) 2015-02-20 2018-04-19 オレゴン・ヘルス・アンド・サイエンス・ユニバーシティ ソベチロムの誘導体
WO2016196646A1 (en) 2015-06-04 2016-12-08 The United States Of America, As Represented By The Secretary, Departmet Of Health & Human Services Cannabinoid receptor mediating compounds
CA2988405A1 (en) 2015-06-11 2016-12-15 University Of Pittsburgh - Of The Commonwealth System Of Higher Education P62-zz chemical inhibitor
US10799580B2 (en) 2015-09-09 2020-10-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Expression vector delivery system and use thereof for inducing an immune response
EP3423448B1 (de) 2016-03-04 2024-12-04 The U.S.A. as represented by the Secretary, Department of Health and Human Services Cannabinoid-rezeptorvermittelnde verbindungen
WO2017165822A1 (en) 2016-03-24 2017-09-28 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Small molecule inhibitor of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer
DK3457851T3 (da) 2016-05-18 2021-09-20 Univ Oregon Health & Science Derivater af sobetirom
EP3471828A1 (de) 2016-06-16 2019-04-24 Acies Bio d.o.o. Zusammensetzungen und verfahren zur behandlung von krankheiten, die durch eine unzureichende pantothenatkinaseaktivität gekennzeichnet sind
TWI648291B (zh) * 2016-10-13 2019-01-21 傑安生技股份有限公司 氧化性修飾改善細胞穿透性胜肽之成藥性以作為藥物載體
US11072642B2 (en) 2016-11-09 2021-07-27 Mayo Foundation For Medical Education And Research MANP analogues
WO2018109220A2 (en) 2016-12-16 2018-06-21 Institute For Research In Biomedicine Novel recombinant prefusion rsv f proteins and uses thereof
WO2018156459A1 (en) 2017-02-22 2018-08-30 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Compounds and methods for inhibiting emt pathways to treat cancer, organ fibrosis and metabolic disorders
IL274130B2 (en) 2017-11-01 2025-08-01 Scripps Research Inst Novel scaffolded hiv-1 vaccine immunogens
WO2019118803A1 (en) 2017-12-14 2019-06-20 The United States Of America, As Represented By The Secretary,Department Of Health And Human Services Chemical entities for lytic activation of kshv and therapeutic targeting of viral enzymes/proteins
SG11202008536QA (en) 2018-03-29 2020-10-29 Elex Biotech Inc Compounds for treatment of cardiac arrhythmias and heart failure
EP3856754A1 (de) 2018-09-25 2021-08-04 The United States of America, as represented by the Secretary, Department of Health and Human Services 2'-halogenierte-4'-thio-2'-deoxy-5-azacytidin-analoga und deren verwendung
WO2020097421A1 (en) 2018-11-09 2020-05-14 Mayo Foundation For Medical Education And Research Combination treatment for resistant hypertension
WO2020123861A1 (en) 2018-12-12 2020-06-18 Autobahn Therapeutics, Inc. Novel thyromimetics
CN113784950A (zh) 2019-03-01 2021-12-10 速通医疗公司 新型拟甲状腺素药
EP3937917B1 (de) 2019-03-11 2023-11-15 Oregon State University Analoga und derivate von cephalotaxin und verfahren zur herstellung und verwendung der verbindungen
AU2020391467A1 (en) 2019-11-29 2022-06-23 Autobahn Therapeutics, Inc. Novel thyromimetics
US20210196648A1 (en) * 2019-12-31 2021-07-01 Industrial Technology Research Institute Drug-containing multilayer film and method for forming the same
CN115515588A (zh) 2020-02-14 2022-12-23 萨克生物研究学院 大环ulk1/2抑制剂
EP4167986A4 (de) 2020-06-17 2024-11-20 Autobahn Therapeutics, Inc. Thyromimetika
EP4168384A4 (de) 2020-06-17 2024-07-10 Autobahn Therapeutics, Inc. Thyromimetika
CN112409765A (zh) * 2020-11-16 2021-02-26 深圳市正旺环保新材料有限公司 一种可降解环保塑料袋及其制备方法
WO2022261296A1 (en) 2021-06-09 2022-12-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compounds that bind non-canonical g-quadruplex structures and methods of making and using the same
GB2613656A (en) * 2021-12-13 2023-06-14 Pharmathen Sa Sustained release injectable pharmaceutical formulation of levothyroxine and process for preparation thereof
WO2023059867A1 (en) 2021-10-08 2023-04-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compounds for treating or preventing alzheimer's disease
WO2023146771A1 (en) 2022-01-25 2023-08-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Gingerenone a prodrugs as senotherapeutics and methods of use
EP4493547A1 (de) 2022-03-14 2025-01-22 The United States of America, as represented by the Secretary, Department of Health and Human Services Verbindungen zur modulierung des cannabinoidrezeptors
WO2024151855A1 (en) 2023-01-13 2024-07-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bicyclic carbamoyl pyridone-based integrase strand transfer inhibitors
WO2025054172A1 (en) 2023-09-05 2025-03-13 E-Star Biotech, LLC Formulations of manp and uses thereof
WO2025196270A1 (en) 2024-03-22 2025-09-25 Limmatech Biologics Ag Outer membrane vesicle vaccines for the prevention of n. gonorrhoeae and methods of making and using thereof
WO2025213007A1 (en) 2024-04-04 2025-10-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services S-hydroxychloroquine, optionally with tauroursodeoxycholic acid and/or 3,3'-diindolylmethane, for treating and/or preventing neurological disorders
WO2026085231A1 (en) 2024-10-16 2026-04-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Integrase strand transfer inhibitors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3297033A (en) * 1963-10-31 1967-01-10 American Cyanamid Co Surgical sutures
US3565869A (en) * 1968-12-23 1971-02-23 American Cyanamid Co Extrudable and stretchable polyglycolic acid and process for preparing same
US3755558A (en) * 1971-02-23 1973-08-28 Du Pont Polylactide drug mixtures for topical application atelet aggregation
US3839297A (en) * 1971-11-22 1974-10-01 Ethicon Inc Use of stannous octoate catalyst in the manufacture of l(-)lactide-glycolide copolymer sutures
US3912692A (en) * 1973-05-03 1975-10-14 American Cyanamid Co Process for polymerizing a substantially pure glycolide composition
US3890283A (en) * 1973-06-04 1975-06-17 American Cyanamid Co Process for post-polymerizing polyglycolic acid
US4249531A (en) * 1979-07-05 1981-02-10 Alza Corporation Bioerodible system for delivering drug manufactured from poly(carboxylic acid)
US4273920A (en) * 1979-09-12 1981-06-16 Eli Lilly And Company Polymerization process and product
PH19942A (en) * 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
US4479911A (en) * 1982-01-28 1984-10-30 Sandoz, Inc. Process for preparation of microspheres and modification of release rate of core material
US4605730A (en) * 1982-10-01 1986-08-12 Ethicon, Inc. Surgical articles of copolymers of glycolide and ε-caprolactone and methods of producing the same
US4523591A (en) * 1982-10-22 1985-06-18 Kaplan Donald S Polymers for injection molding of absorbable surgical devices
CH656884A5 (de) * 1983-08-26 1986-07-31 Sandoz Ag Polyolester, deren herstellung und verwendung.
JPS60100516A (ja) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法

Also Published As

Publication number Publication date
DE3688213T2 (de) 1993-09-23
DE3688213D1 (de) 1993-05-13
JP2551756B2 (ja) 1996-11-06
US4849228A (en) 1989-07-18
EP0202065A2 (de) 1986-11-20
CA1262005A (en) 1989-09-26
JP2660401B2 (ja) 1997-10-08
ATE87946T1 (de) 1993-04-15
HU196703B (en) 1989-01-30
EP0202065B1 (de) 1993-04-07
HUT43488A (en) 1987-11-30
JPH08169818A (ja) 1996-07-02
US4728721A (en) 1988-03-01
EP0202065A3 (en) 1987-10-21
JPS6254760A (ja) 1987-03-10

Similar Documents

Publication Publication Date Title
EP0202065B1 (de) Polymer, seine Herstellung und Verwendung
US5585460A (en) Biodegradable high-molecular polymers, production and use thereof
EP0442671B1 (de) Mikrokapseln mit verzögerter Wirkstoffabgabe
NL194577C (nl) Preparaat voor de lang aanhoudende en gecontroleerde afgifte van medicamenteuze stoffen.
DE69333817T2 (de) Leuprorelinpräparat mit verzögerter Wirkstoffabgabe
EP0302582B2 (de) System zur Freisetzung von Medikamenten und dessen Herstellungsmethode
CA2105374C (en) Method of producing sustained-release microcapsules
Bodmeier et al. Pseudoephedrine HCl microspheres formulated into an oral suspension dosage form
DE3345314A1 (de) Oligomere hydroxycarbonsaeurederivate, deren herstellung und verwendung
DE69624426T2 (de) Verfahren zur Herstellung einer Zubereitung mit verzögerter Freisetzung
EP0595030A2 (de) Mehrkern-Mikrosphären mit verzögerter Wirkstoffabgabe und Verfahren zu deren Herstellung
IE83404B1 (en) Polyethylene-polylactic acid block copolymer nanoparticles
LV10055B (en) Prolonged release preparation and polymers thereof
CH690491A5 (de) Mikroteilchen zur Injektion und ihre Herstellungsverfahren.
EP1420762A1 (de) Verfahren zum entfernen von lösungsmittelrückständen, sowie mit diesem verfahren erhältliche mikropartikel
Yeh et al. Improving the delivery capacity of microparticle systems using blends of poly (DL-lactide co-glycolide) and poly (ethylene glycol)
GB1592829A (en) Absorbable pharmaceutical compositions based on poly (alkylene oxalates)
JP3200706B2 (ja) 生体内分解型高分子重合物
IE883110L (en) Polyester based compositions for controlled release
KR20040066548A (ko) 생리활성펩타이드의 국소투여용 서방성 마이크로스피어 및그 제조방법
EP0724880A1 (de) Verfahren zur Einkapselung von Chlorpheniramine
JP2001192439A (ja) 生体内分解型高分子重合物
HK1054689B (en) Microparticles with an improved release profile and method for the production thereof
HK1054689A1 (en) Microparticles with an improved release profile and method for the production thereof

Legal Events

Date Code Title Description
PF Patent in force
CHPA Change of a particular in the register (except of change of ownership)
PE Patent expired

Effective date: 20060505